Trial Profile

Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary)
Indications Breast cancer; Colon cancer; Colorectal cancer
Focus Pharmacokinetics

Most Recent Events

22 Aug 2013 New trial record
01 Feb 2013 Primary endpoint 'Peak-drug-concentration' has been met.
01 Feb 2013 Primary endpoint 'Drug-bioavailability' has been met.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com